Florida-based Cryo-Cell International, a leader in stem cell cryopreservation, has partnered with Cryopraxis, a Brazil-based company known for its expertise in regenerative technology. The partnership will allow Cryopraxis to conduct clinical studies using Cryo-Cell`s proprietary C`elle menstrual stem cell technology (MenSCs) to identify potential future diagnostic and therapeutic uses for endometriosis and stress urinary incontinence in women.
Cryo-Cell’s C’elle service enables women to collect and cryopreserve stem cells from menstrual blood and is the only one of its kind. Menstrual fluid has been proven to contain undifferentiated adult stem cells and therefore present the potential for future utilization by the donor or possibly first-degree relatives in a manner similar to umbilical cord blood stem cells.
This partnership will support a new field of stem cell research which focuses on the potential benefits of a new and non-invasive way to diagnose endometriosis. The possible test will be based on analyses of the menstrual blood stem cells, which will be collected using Cryo-Cell`s C`elle (SM) system.
Endometriosis is a painful condition that affects approximately five million American women. The condition is caused when the lining of the uterus grows outside of the uterus, resulting in scar tissue that causes severe pelvic pain and may lead to infertility. Diagnosis of endometriosis often comes long after the onset of symptoms, with an average delay of ten years. Endometriosis is commonly diagnosed through laparoscopic procedures that are painful and invasive.
"This research will determine if the stem cells found in menstrual blood can accurately provide a diagnosis that is highly precise, and this approach would offer women the added benefit of being both non-invasive and cost-effective," stated Eduardo Cruz, founder & CEO of Cryopraxis Cryobiology Ltd. "Additionally, this new method would potentially allow for earlier diagnosis of the disease, and subsequently enable women to seek relief from their symptoms sooner."
Cryopraxis will also utilize C`elle stem cells to develop potential therapies for female stress urinary incontinence, a condition primarily caused by a deficiency in the muscles that affect urine flow. Since stem cells isolated from menstrual fluid have the ability to contract, research will determine whether injecting the cells into the urethra would restore the contractility of the muscles and sphincters.
Mercedes A. Walton, Cryo-Cell`s Chairman and CEO commented about the partnership in the company’s announcement, saying, "Millions of women may potentially benefit from the affordable and non-invasive collection of these valuable stem cells today with C`elle service, for the future possible treatment of these two conditions that are painful, pervasive and costly to treat."
Cryo-Cell reports that the company continues to actively expand its portfolio of research collaborations with world-renowned scientists committed to study this stem cell population for a broad range of regenerative therapeutic development, and even cosmeceutical applications.